Page 177 - Read Online

Hjalgrim et al. J Transl Genet Genom 2022;6:134-46 https://dx.doi.org/10.20517/jtgg.2021.46 Page 146

78. Cader FZ, Hu X, Goh WL, et al. A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin
lymphoma. Nat Med 2020;26:1468-79. DOI PubMed
79. Veldman J, Visser L, Berg AVD, Diepstra A. Primary and acquired resistance mechanisms to immune checkpoint inhibition in
Hodgkin lymphoma. Cancer Treat Rev 2020;82:101931. DOI PubMed
80. Diepstra A, Poppema S, Boot M, et al. HLA-G protein expression as a potential immune escape mechanism in classical Hodgkin’s
lymphoma. Tissue Antigens 2008;71:219-26. DOI PubMed
81. Bartlett NL, Herrera AF, Domingo-Domenech E, et al. A phase 1b study of AFM13 in combination with pembrolizumab in patients
with relapsed or refractory Hodgkin lymphoma. Blood 2020;136:2401-9. DOI PubMed PMC
82. Csizmar CM, Ansell SM. Engaging the innate and adaptive antitumor immune response in lymphoma. Int J Mol Sci 2021;22:3302.
DOI PubMed PMC
83. Chan TSY, Hwang YY, Khong PL, et al. Low-dose pembrolizumab and nivolumab were efficacious and safe in relapsed and
refractory classical Hodgkin lymphoma: experience in a resource-constrained setting. Hematol Oncol 2020;38:726-36. DOI PubMed